{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/raynauds-phenomenon/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"9a10980a-a167-52bd-9991-be6f6cd68c50","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field b576b6db-1c1f-451e-821c-6ec366e8a13d --><h2>How should I assess a person with suspected Raynaud's phenomenon?</h2><!-- end field b576b6db-1c1f-451e-821c-6ec366e8a13d -->","summary":"","htmlStringContent":"<!-- begin item d09c7703-1853-47c7-91f2-501d468039f5 --><!-- begin field a31379fd-a990-4c33-85ea-bfcf615ed082 --><p><strong>Take a history asking about:</strong></p><ul><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/diagnosis/clinical-features/\">Symptoms</a> including:</strong><ul><li>Colour change of digits or other extremities.</li><li>Associated features (such as numbness, paraesthesia on rewarming or pain).</li><li>Triggers for attacks.</li><li>Frequency and severity of attacks.</li></ul></li><li><strong>Age at onset</strong>.</li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/background-information/complications/\">Complications</a></strong> such as digital ulceration</li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/background-information/causes-of-or-diseases-associated-with-raynauds-phenomenon/\">Drugs</a></strong> which may precipitate or exacerbate Raynaud’s phenomenon.</li><li><strong>Family history</strong> of Raynaud’s phenomenon or connective tissue disorder.</li><li><strong>Smoking and occupation</strong> — to identify occupational causes of symptoms (such as hand arm vibration syndrome) and exposure to chemicals (such as vinyl chloride).</li><li><strong>Past medical history and systems review</strong> to identify symptoms associated with <a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/background-information/causes-of-or-diseases-associated-with-raynauds-phenomenon/\">underlying conditions</a> for example:<ul><li>Morning joint stiffness, swollen joints, rash, photosensitivity, hair loss, oral or nasal ulceration, significant dry eyes or dry mouth, puffy hands, symptoms of oesophageal dysmotility or gastro-oesophageal reflux disease, muscle weakness, breathlessness, and weight loss.</li></ul></li></ul><p><strong>Examine the person, checking:</strong></p><ul><li>The skin and nails looking for <a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/background-information/complications/\">complications</a> of Raynaud’s phenomenon such as digital ischaemic lesions (digital pitting, ulceration or gangrene) and features of <a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/background-information/causes-of-or-diseases-associated-with-raynauds-phenomenon/\">associated conditions</a> such as systemic sclerosis.<ul><li>As clinical signs may not be present at the time of assessment, asking the person to take a photograph of affected digits during an attack can be helpful.</li><li>Abnormal nail-fold capillaries (best viewed with a dermatoscope) are highly suggestive of underlying connective tissue disease — referral to a rheumatologist for further evaluation is indicated if abnormalities are suspected.</li></ul></li><li>The peripheral pulses and blood pressure in both arms — to assess for <a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/background-information/causes-of-or-diseases-associated-with-raynauds-phenomenon/\">vascular causes</a> of symptoms.</li></ul><p><strong>Arrange investigations including:</strong></p><ul><li>Full blood count (FBC), erythrocyte sedimentation rate (ESR), and antinuclear antibodies (ANA).</li><li>Other tests may be indicated if an <a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/background-information/causes-of-or-diseases-associated-with-raynauds-phenomenon/\">underlying condition</a> is suspected.</li></ul><!-- end field a31379fd-a990-4c33-85ea-bfcf615ed082 --><!-- end item d09c7703-1853-47c7-91f2-501d468039f5 -->","topic":{"id":"255ee7a1-48e0-54c2-a732-4e03fba17a60","topicId":"e0f3a627-69e7-4258-bfd3-06ad68e3ba94","topicName":"Raynaud's phenomenon","slug":"raynauds-phenomenon","lastRevised":"Last revised in February 2020","chapters":[{"id":"0209e319-b6f4-5f73-ae5c-6afd753453ea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9bb70ded-aa7a-5909-9d84-111f559bccc8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"47c14b87-688e-5e8e-af1c-e6614c461561","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ad9e53ac-9556-5bdd-aa04-09e22fccd689","slug":"changes","fullItemName":"Changes"},{"id":"aa95064f-a6c4-5317-a6ec-33fca3665fa5","slug":"update","fullItemName":"Update"}]},{"id":"0346daa7-fb38-5512-b2c8-7f0d5d4b7c91","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"074b9165-8cc3-56b5-a9fa-483516a026aa","slug":"goals","fullItemName":"Goals"},{"id":"dadcf48d-9a98-54cf-baab-c0b65179b8f1","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d272b294-ed60-5488-8640-d756cbe670a3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9dcdeaed-4201-583c-a5a9-5dcb4ead9acb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c107602-0bb8-52d9-b277-5639494a105e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72ac11d0-1027-5c50-ae82-9ae1e1bf92b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0559a1bc-62df-54ef-846b-db71b06fbe87","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2ec7ca08-f644-50e8-b54e-c6378c7053b0","slug":"definition","fullItemName":"Definition"},{"id":"951db58c-3bcb-56ef-be5f-1e0fd9fdbd81","slug":"causes-of-or-diseases-associated-with-raynauds-phenomenon","fullItemName":"Causes of, or diseases associated with Raynaud's phenomenon:"},{"id":"b9b9e063-b592-5419-8f15-8f350c8de255","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"16789ea7-d3e6-5c24-a51f-e9f57845b88b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b914d639-5ff2-526f-86e9-1280331ece9b","slug":"complications","fullItemName":"Complications"}]},{"id":"1478d9b3-2ba3-5103-9fab-2a67d58f88f4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"509776f6-588e-5896-9432-bf45ef2f63e1","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"9a10980a-a167-52bd-9991-be6f6cd68c50","slug":"assessment","fullItemName":"Assessment"},{"id":"ab1aab22-cf2f-584c-b073-a5bba7ae4c6d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"143745f3-74bd-57da-b042-3dd311837d98","fullItemName":"Management","slug":"management","subChapters":[{"id":"f6006983-20db-5702-8a8c-9763d45ab3cf","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ede08fed-d06c-5c6c-9c34-9ada648e6c09","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"1c7cb268-2a82-5737-b0ee-332487a61ea1","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"f6403106-c5ec-5705-bdcf-a225c5de60f9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8a93fc9c-f20c-58a4-a5db-33420cd3b27a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e2a1391d-6c3d-5d36-b072-abc59f16980c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"bfa3b4f4-feec-59d7-9574-f36fc1bcf5cd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"18ed7dfb-e0e7-5be9-9a57-0ab24f1666c5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2bf5741c-d447-5f96-8155-861976265e79","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"52d565ac-2dac-556a-9bc8-c5c8946df2ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1b7e64ea-3359-5d63-93ff-6b661619a25e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1478d9b3-2ba3-5103-9fab-2a67d58f88f4","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"66fdc62a-8141-5c7f-84f1-e0256b0f2ee3","slug":"basis-for-recommendation-64f","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 62d5c7be-16be-4fed-beb6-77c1e5399da1 --><h3>Basis for recommendation</h3><!-- end field 62d5c7be-16be-4fed-beb6-77c1e5399da1 -->","summary":null,"htmlStringContent":"<!-- begin item 64fc8b72-4ce1-4f67-83d9-1bcdfd33fbf0 --><!-- begin field dee1b463-1e9b-44f2-8e56-d40bc7e08ad5 --><p>The recommendations on the assessment of a person with suspected Raynaud’s phenomenon are based on clinical guidelines <em>International consensus criteria for the diagnosis of Raynaud's phenomenon</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Maverakis, 2014</a>], <em>Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>],<em> </em>and <em>European Society for Vascular Medicine (ESVM) guidelines - the diagnosis and management of Raynaud's</em> <em>phenomenon</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Linnemann, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Pain, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Wigley, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Herrick, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Ingegnoli, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Shapiro, 2017</a>].</p><h4>Differentiation between primary and secondary Raynaud’s phenomenon</h4><ul><li>A detailed clinical assessment is essential to help differentiate between primary and secondary Raynaud’s phenomenon as prognosis and management differ significantly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>]. Raynaud’s phenomenon is often a presenting feature of connective tissue disorders (in particular systemic sclerosis) and early diagnosis may reduce later morbidity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].<ul><li>Raynaud’s phenomenon occurs in 90 % of patients with systemic sclerosis, 10–45 % of people with systemic lupus erythematosus, 33 % of people with Sjögren’s syndrome, and in 20 % of people with dermatomyositis/polymyositis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].</li><li>The overall prevalence of Raynaud’s phenomenon in people with rheumatoid arthritis is similar to the general population (10 %) but symptoms tend to be more severe [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].</li></ul></li><li>Primary Raynaud’s phenomenon tends to develop at a younger age (typically the second or third decade) than secondary Raynaud’s phenomenon [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Maverakis, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hinze, 2018</a>].</li><li>Family history is often positive in primary Raynaud’s phenomenon [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].</li><li>Careful examination of the hands is needed to identify features consistent with a secondary cause of Raynaud’s phenomenon (such as ulceration, tissue necrosis or gangrene, calcinosis, and skin fibrosis) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Maverakis, 2014</a>].<ul><li>Sclerodactyly, digital pitting, dilated nailfold capillaries (sometimes visible to the naked eye) and telangiectasia are suggestive of systemic sclerosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Herrick, 2017</a>].</li><li>Nailfold capillaroscopy is recommended in clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>] and several review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Linnemann, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Ennis, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Pain, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Wigley, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Herrick, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Ingegnoli, 2017</a>] as abnormalities are suggestive of an underlying connective tissue disorder — unless expertise is available locally this is usually carried out in secondary care.</li></ul></li></ul><h4>Investigations</h4><ul><li>Expert opinion in guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Linnemann, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Ennis, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Herrick, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">BMJ Best Practice, 2019</a>] is that in the presence of typical symptoms a normal erythrocyte sedimentation rate, full blood count and thyroid function tests and negative testing for antinuclear antibodies is highly suggestive of primary Raynaud’s phenomenon. These blood tests are usually a sufficient primary care screen unless clinical features suggest a secondary cause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].</li><li>If a secondary cause is suspected, referral to rheumatology for further assessment and management is indicated — urgency of referral will be dependent on the specific clinical situation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>].</li></ul><!-- end field dee1b463-1e9b-44f2-8e56-d40bc7e08ad5 --><!-- end item 64fc8b72-4ce1-4f67-83d9-1bcdfd33fbf0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}